Natallia Rameika

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Ingår i Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI för NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Ladda ner fulltext (pdf) av NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Zhang, Xiaonan; Rameika, Natallia; Zhong, Lei; Veanes, Margus et al.

Ingår i EBioMedicine, 2024

• DOI för Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
• Ladda ner fulltext (pdf) av Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Next generation pan-cancer blood proteome profiling using proximity extension assay

Alvez, Maria Bueno; Edfors, Fredrik; von Feilitzen, Kalle; Zwahlen, Martin et al.

Ingår i Nature Communications, 2023

• DOI för Next generation pan-cancer blood proteome profiling using proximity extension assay
• Ladda ner fulltext (pdf) av Next generation pan-cancer blood proteome profiling using proximity extension assay

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Rendo, Verónica; Kundu, Snehangshu; Rameika, Natallia; Ljungström, Viktor et al.

Ingår i Scientific Reports, 2020

• DOI för Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
• Ladda ner fulltext (pdf) av Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

Åkerrén Ögren, Jim; Ekström, Joakim; Rameika, Natallia; Torell, Emma et al.

Ingår i Molecular Cancer, 2026

• DOI för Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers
• Ladda ner fulltext (pdf) av Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Ingår i Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI för NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Ladda ner fulltext (pdf) av NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

A human pan-disease blood atlas of the circulating proteome

Álvez, María Bueno; Bergström, Sofia; Kenrick, Josefin; Johansson, Emil et al.

Ingår i Science, 2025

• DOI för A human pan-disease blood atlas of the circulating proteome

Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Lindell, Emma; Guo, Jing; Zhao, Miao; Rameika, Natallia et al.

Ingår i Cell Death and Disease, 2025

• DOI för Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma
• Ladda ner fulltext (pdf) av Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Targeting loss of heterozygosity in cancer

Rameika, Natallia

2025

• Ladda ner fulltext (pdf) av Targeting loss of heterozygosity in cancer

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

Åkerrén Ögren, Jim; Ekström, Joakim; Rameika, Natallia; Torell, Emma et al.

Ingår i Molecular Cancer, 2026

• DOI för Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers
• Ladda ner fulltext (pdf) av Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Ingår i Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI för NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Ladda ner fulltext (pdf) av NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

A human pan-disease blood atlas of the circulating proteome

Álvez, María Bueno; Bergström, Sofia; Kenrick, Josefin; Johansson, Emil et al.

Ingår i Science, 2025

• DOI för A human pan-disease blood atlas of the circulating proteome

Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Lindell, Emma; Guo, Jing; Zhao, Miao; Rameika, Natallia et al.

Ingår i Cell Death and Disease, 2025

• DOI för Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma
• Ladda ner fulltext (pdf) av Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Zhang, Xiaonan; Rameika, Natallia; Zhong, Lei; Veanes, Margus et al.

Ingår i EBioMedicine, 2024

• DOI för Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
• Ladda ner fulltext (pdf) av Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Next generation pan-cancer blood proteome profiling using proximity extension assay

Alvez, Maria Bueno; Edfors, Fredrik; von Feilitzen, Kalle; Zwahlen, Martin et al.

Ingår i Nature Communications, 2023

• DOI för Next generation pan-cancer blood proteome profiling using proximity extension assay
• Ladda ner fulltext (pdf) av Next generation pan-cancer blood proteome profiling using proximity extension assay

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity

Zhang, Xiaonan; Akcan, Ece; Correia, Mario S. P.; Rameika, Natallia et al.

Ingår i Biochemical Pharmacology, 2022

• DOI för Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity
• Ladda ner fulltext (pdf) av Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Rendo, Verónica; Kundu, Snehangshu; Rameika, Natallia; Ljungström, Viktor et al.

Ingår i Scientific Reports, 2020

• DOI för Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
• Ladda ner fulltext (pdf) av Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Targeting loss of heterozygosity in cancer

Rameika, Natallia

2025

• Ladda ner fulltext (pdf) av Targeting loss of heterozygosity in cancer

Identification of novel target genes for LOH-based cancer therapy

Rameika, Natallia; Veanes, Margus; Akcan, Ece; Kundu, Snehangshu et al.

Novel anti-cancer agents targeting NAT2 loss in colorectal cancer

Rameika, Natallia; Tsiara, Ioanna; Haberek, Wawrzyniec; Akcan, Ece et al.